Clinical candidate in ABX-01 programme, CTX-187, currently in development ahead of first in-human clinical trials to target Gram-negative bacterial infections -- Investment from the world's largest ...
British immunotherapy company Centauri Therapeutics received a ₤6 million ($8.1 million USD) investment from the AMR Action Fund to support development of its broad-spectrum antibiotic candidate, ...
Centauri Therapeutics, a Cheshire-based immunotherapy company, has secured £6m from the AMR Action Fund, extending the firm's Series A round to £30m.
Alpha Centauri, one of the two "Pointer Stars" that help stargazers find the Southern Cross in the Southern Hemisphere, may have a planet in orbit around it. If it does, the Webb Telescope will find ...
News-Medical.Net on MSN
Centauri Therapeutics extends Series A to £30 M with £6 M investment from AMR Action Fund to support progression of lead clinical candidate
Centauri Therapeutics Limited ('Centauri'), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, today announced it has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results